13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management

Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management

Cognitive and neuropsychiatric complaints in older adults represent one of the most common and challenging clinical presentations in advanced practice primary care. The "3 Ds"—Delirium, Dementia (Major Neurocognitive Disorder), and Depression—frequently co-occur in the same patient, creating diagnostic confusion and risking therapeutic misadventure. For the AGPCNP, executing a rigorous, structured differential diagnosis is paramount to identifying reversible medical emergencies, establishing precise neurocognitive prognoses, and initiating goal-concordant therapies.

---

1. Master Differential Diagnostic Matrix: The 3 Ds

+---------------------------------------------------------------------------------------------------+
|                         MASTER DIFFERENTIAL: DELIRIUM vs. DEMENTIA vs. DEPRESSION                 |
|                                                                                                   |
|   CLINICAL FEATURE      DELIRIUM                    DEMENTIA                    DEPRESSION        |
|   ================      ========                    ========                    ==========        |
|   Onset                 Acute (hours to days)       Insidious (months/years)    Subacute (weeks)  |
|   Course                Fluctuating (wax/wane)      Progressive, steady decline Diurnal (AM worse)|
|   Duration              Days to weeks               Years to decades            Months to years   |
|   Consciousness         Altered / Fluctuating       Intact until end stage      Intact / Normal   |
|   Attention             Severely Impaired           Intact early, declines late Variable / Intact |
|   Orientation           Impaired (fluctuating)      Impaired progressively      Intact / May miss |
|   Memory                Impaired recall/immediate   Loss of recent/short-term   Patchy / Effortful|
|   Testing Response      Incoherent / Inattentive    Tries hard, covers errors   "I don't know"    |
|   Perception            Visual Hallucinations common Absent early (except LBD)  Rare/Mood-congruent|
|   Reversibility         HIGHLY REVERSIBLE           Generally IRREVERSIBLE      HIGHLY REVERSIBLE |
+---------------------------------------------------------------------------------------------------+

Clinical Interrogation of Cognitive Testing Responses

• Dementia: Patients typically demonstrate a lack of insight (anosognosia), minimize their cognitive deficits, attempt to answer questions cheerfully or make plausible guesses (confabulation), and look to family members for reassurance or answers (head-turning sign).
• Depression ("Pseudodementia"): Patients actively emphasize and lament their memory failures ("My brain is completely gone, I can't remember anything"), exhibit profound psychomotor slowing, and respond to cognitive test items with rapid, unmotivated "I don't know" answers without attempting recall.
• Delirium: Patients are unable to sustain focused attention long enough to complete testing, display fragmented thinking, exhibit perceptual distortions (illusions/hallucinations), and fluctuate in alertness between somnolence and agitation.

---

2. Delirium: Pathophysiology, Subtypes & Structured Workup

Delirium is a medical emergency representing acute, diffuse cerebral metabolic failure. The underlying neurobiology involves widespread central cholinergic hypofunction, excess dopaminergic and glutamatergic signaling, and microglial activation triggered by systemic neuroinflammation.

+---------------------------------------------------------------------------------------------------+
|                         CONFUSION ASSESSMENT METHOD (CAM) ALGORITHM                               |
|                                                                                                   |
|   FEATURE 1: Acute Onset and Fluctuating Course                                                   |
|   - Evidence of acute mental status change from baseline corroborated by family/nursing?          |
|   - Does abnormal behavior fluctuate during the day (waxing and waning)?                         |
|                                     AND                                                           |
|   FEATURE 2: Inattention                                                                          |
|   - Difficulty focusing attention? (e.g., unable to spell 'WORLD' backward, count down 20 to 1,   |
|     or perform digit span test)? Easily distracted by environmental stimuli?                      |
|                                     AND                                                           |
|                  (MUST EXHIBIT EITHER FEATURE 3 OR FEATURE 4)                                     |
|                                     / \                                                           |
|                                    /   \                                                          |
|                                   v     v                                                         |
|   FEATURE 3: Disorganized Thinking       FEATURE 4: Altered Level of Consciousness                |
|   - Incoherent, rambling, illogical,      - Any state other than 'Alert':                         |
|     tangential flow of ideas, or            * Hyperalert / Agitated                               |
|     unpredictable topic switching.          * Lethargic / Somnolent                               |
|                                             * Stuporous / Semi-comatose                           |
|                                                                                                   |
|   DIAGNOSTIC RULE: [Feature 1] + [Feature 2] + EITHER [Feature 3] OR [Feature 4] = DELIRIUM       |
+---------------------------------------------------------------------------------------------------+

Delirium Motoric Subtypes

1. Hyperactive Delirium (~20–25%): Agitation, restlessness, emotional lability, hypervigilance, combative behavior, pulling at intravenous lines or urinary catheters, vivid hallucinations. Easiest to recognize.
2. Hypoactive Delirium (~50–60%): Lethargy, somnolence, psychomotor retardation, apathy, staring into space, decreased verbal output. Most frequently misdiagnosed as depression or worsening dementia and carries the highest mortality rate due to delayed medical evaluation.
3. Mixed Delirium (~20–25%): Rapid nocturnal-diurnal cycling between hyperactive agitation and daytime hypoactive somnolence.

Etiological Workup: The "I WATCH DEATH" Framework

Delirium Management Principles

• Non-Pharmacological Protocols (Hospital Elder Life Program - HELP): First-line and most effective intervention. Includes regular reorientation (clocks, calendars, familiar objects), maintaining circadian sleep-wake cycles (natural daylight, quiet at night), sensory optimization (ensuring working glasses and hearing aids are worn), early physical mobilization, avoidance of physical restraints, and maintaining adequate hydration/nutrition.
• Pharmacological Restraint Rules: Antipsychotics have no prophylactic role in delirium and do not shorten delirium duration. Pharmacotherapy (e.g., low-dose Haloperidol 0.5–1 mg or Quetiapine 12.5–25 mg) is strictly indicated only when severe hyperactive agitation threatens immediate physical harm to self or staff (e.g., pulling endotracheal tube). Avoid benzodiazepines entirely (which worsen delirium), unless managing alcohol or sedative withdrawal.

---

3. Major Neurocognitive Disorders (Dementia Subtypes)

Major Neurocognitive Disorder (DSM-5) requires significant cognitive decline in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor, or social cognition) that interferes with independence in everyday activities (requiring assistance with IADLs/ADLs).

+---------------------------------------------------------------------------------------------------+
|                         NEUROPATHOLOGICAL LOCALIZATION OF DEMENTIAS                               |
|                                                                                                   |
|   [ALZHEIMER'S DISEASE]                                                                           |
|   - Medial Temporal Lobes & Hippocampus -> Anterograde Episodic Memory Loss, Anomia, Apraxia       |
|   - Neuropathology: Extracellular Beta-Amyloid Plaque deposition & Intracellular Tau Tangles       |
|                                                                                                   |
|   [VASCULAR DEMENTIA]                                                                             |
|   - Subcortical White Matter & Frontostriatal Circuits -> Stepwise Decline, Executive Dysfunction |
|   - Neuropathology: Multiple lacunar infarcts, microvascular ischemic leukoaraiosis                |
|                                                                                                   |
|   [LEWY BODY DEMENTIA]                                                                            |
|   - Cortical & Substantia Nigra Alpha-Synuclein Inclusions -> Visual Hallucinations, Parkinsonism |
|   - Neuropathology: Cytoplasmic Lewy Bodies; Severe Neuroleptic Hypersensitivity                  |
|                                                                                                   |
|   [FRONTOTEMPORAL DEMENTIA]                                                                       |
|   - Frontal & Anterior Temporal Lobes -> Early Disinhibition, Loss of Empathy, Hyperorality       |
|   - Neuropathology: Pick bodies (tau or TDP-43 inclusions); Preserved Visuospatial Function       |
+---------------------------------------------------------------------------------------------------+

Detailed Subtype Comparison

---

4. Dementia Pharmacotherapy & Practice Guidelines

+---------------------------------------------------------------------------------------------------+
|                         DEMENTIA PHARMACOTHERAPY SPECTRUM                                         |
|                                                                                                   |
|   [CHOLINESTERASE INHIBITORS (ChEIs)]                                                             |
|   - Agents: Donepezil (5-10 mg daily), Rivastigmine (oral / transdermal patch), Galantamine       |
|   - Mechanism: Reversible inhibition of acetylcholinesterase, increasing synaptic acetylcholine   |
|   - Indications: Mild to Moderate Alzheimer's, Lewy Body Dementia, Vascular Dementia             |
|   - Adverse Effects: Nausea, diarrhea, anorexia, weight loss, severe bradycardia, syncope, insomnia|
|   - Clinical Pearl: Rivastigmine transdermal patch bypasses GI tract, reducing nausea/diarrhea   |
|                                                                                                   |
|   [NMDA RECEPTOR ANTAGONISTS]                                                                     |
|   - Agent: Memantine (5-20 mg daily, titrate weekly)                                              |
|   - Mechanism: Uncompetitive NMDA receptor antagonist; blocks pathological glutamate excitotoxicity|
|   - Indications: Moderate to Severe Alzheimer's Disease (MMSE <15-20); add to Donepezil          |
|   - Adverse Effects: Dizziness, headache, confusion, constipation; dose-reduce in CKD             |
|                                                                                                   |
|   [ANTI-AMYLOID MONOCLONAL ANTIBODIES (2023-2026 Landscape)]                                      |
|   - Agents: Lecanemab, Donanemab                                                                  |
|   - Mechanism: Binds and clears soluble amyloid-beta protofibrils and plaques in cerebral cortex   |
|   - Indications: Mild Cognitive Impairment (MCI) or Mild Dementia due to confirmed AD pathology    |
|   - Critical Safety Surveillance: Regular Brain MRI monitoring for ARIA (Amyloid-Related Imaging   |
|     Abnormalities: ARIA-E [vasogenic edema] and ARIA-H [microhemorrhages/superficial siderosis]);  |
|     ApoE ε4 homozygous status carries the highest risk of severe ARIA.                            |
+---------------------------------------------------------------------------------------------------+

Management of Behavioral and Psychological Symptoms of Dementia (BPSD)

Agitation, aggression, wandering, and delusions occur in up to 90% of dementia patients over the disease course.

• Non-Pharmacological First (DICE Framework): Describe the specific behavior; Investigate underlying triggers (unmanaged pain, constipation, urinary retention, cold/hot, noisy environment, fear); Create targeted non-pharmacological caregiver interventions; Evaluate efficacy.
• FDA Black-Box Warning on Antipsychotics: All first- and second-generation antipsychotics carry an explicit Black-Box Warning for a 1.6- to 1.7-fold increase in all-cause mortality (primarily from stroke, aspiration pneumonia, and sudden cardiac death) when used in older adults with dementia-related psychosis. If non-pharmacologic measures fail and severe psychotic agitation threatens safety, obtain documented surrogate informed consent, use lowest effective dose of atypical antipsychotics (Quetiapine 12.5–25 mg, Risperidone 0.25–0.5 mg), and reassess for tapering within 3–6 months.

---

5. Geriatric Depression & "Pseudodementia"

Late-life depression often presents atypically with somatic complaints, anorexia, uncharacteristic anxiety, and cognitive complaints rather than classic depressed mood.

Clinical Evaluation and Diagnostic Tools

• Geriatric Depression Scale (GDS-15): Validated 15-item binary (Yes/No) questionnaire that excludes somatic symptoms to avoid confounding by physical illness. Score $\ge 5$ suggests depression; score $\ge 10$ is highly sensitive and specific for major depressive episode.
• Depression-Induced Cognitive Impairment (Pseudodementia): A reversible syndrome where severe depressive disorder causes pronounced executive dysfunction, psychomotor slowing, and memory retrieval deficits. When treated with effective antidepressant therapy, cognitive performance returns to baseline.

Safe Antidepressant Selection in Older Adults

• Preferred First-Line SSRIs: Sertraline (25–100 mg/day) and Escitalopram (5–10 mg/day) have minimal drug-drug interactions and benign cardiovascular profiles. Monitor for SSRI-induced hyponatremia / SIADH and GI bleeding risk.
• Agents to Avoid: Fluoxetine (excessively long half-life and potent CYP2D6/CYP3A4 inhibition) and Paroxetine (potent anticholinergic properties causing sedation, constipation, and cognitive worsening).
• Alternative Agents: Duloxetine (SNRI; highly effective for co-existing diabetic peripheral neuropathy, fibromyalgia, or chronic osteoarthritis pain; monitor blood pressure); Mirtazapine (Noradrenergic and specific serotonergic antidepressant; potent 5-HT2/3 and H1 blockade promoting appetite stimulation, weight gain, and sedation at low doses 7.5–15 mg, ideal for depressed patients with severe insomnia and cachexia).

---

6. Board-Yield Summary & Clinical Pearls

+---------------------------------------------------------------------------------------------------+
|                                 ANCC AGPCNP CLINICAL EXAM PEARLS                                  |
|                                                                                                   |
|   - Acute cognitive decline + fluctuating inattention is DELIRIUM until proven otherwise.         |
|     Never attribute sudden confusion to 'worsening dementia' without ruling out infection or ADEs.|
|                                                                                                   |
|   - If a clinical vignette describes a patient with fluctuating cognition, spontaneous           |
|     parkinsonism, and vivid, detailed visual hallucinations of animals or small children, the     |
|     diagnosis is LEWY BODY DEMENTIA. Never prescribe Haloperidol (severe fatal rigidity risk!).    |
|                                                                                                   |
|   - A patient presenting with progressive wide-based 'magnetic' gait ataxia, urinary urge          |
|     incontinence, and cognitive slowing ('Wet, Wobbly, Wacky') has Normal Pressure Hydrocephalus.  |
|     A high-volume therapeutic lumbar puncture is both diagnostic and temporarily curative.        |
|                                                                                                   |
|   - In geriatric depression with anorexia and severe insomnia, Mirtazapine 7.5-15 mg at bedtime is |
|     the board-favored agent due to appetite-stimulating and sedating antihistaminic properties.   |
+---------------------------------------------------------------------------------------------------+